Key facts: Novo Nordisk's $500M Ad Spend Surpasses Eli Lilly; Stock Drops
I'm PortAI, I can summarize articles.
In early 2025, Novo Nordisk spent nearly $500 million on U.S. ads for its GLP-1 drugs, Wegovy and Ozempic, surpassing Eli Lilly's ad budget for rival products.1Novo Nordisk (NOVO_B) fell over 2% in early European trading, amid a wider drop in European pharma stocks following the U.S. Medicare's proposed lower payment rates for 2027.2Novo Nordisk's Wegovy pill version is gaining popularity, especially among men, due to its convenience and a lower starting price of $149 per month.3
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments